Bareilly (UP), January 27, 2026 (ANI): Alankar Agnihotri, who resigned as City Magistrate of Bareilly on Tuesday, alleged that an “anti-Brahmin campaign” has been ongoing in the Uttar Pradesh ...

Critical Role Campaign 4 has already been a wild ride for Dungeons and Dragons fans, but Mulligan's latest house rule is on a whole different level. Now, viewers have official confirmation as to why ...

Sign up to receive CFR President Mike Froman’s analysis on the most important foreign policy story of the week, delivered to your inbox every Friday. Subscribe to ...

Cedars-Sinai investigators, leading a multi-institutional team, have developed and validated a tool to predict which patients with pancreatic neuroendocrine tumors (PanNETs) need closer monitoring ...

Novartis has tapped up an artificial-intelligence-enabled British biotech for a $1.7 billion biobucks deal to discover new targets for immuno-dermatology conditions. What caught the Swiss pharma’s eye ...

When Amanda Smith walked into the kitchen one night in 2015 to warm up a bottle for her four-month-old daughter, she couldn’t make out the numbers on the microwave. They were blurry. They’d never been ...

X has finally revealed its long-promised chat platform, which replaces the service's basic DM functionality with features more like the messaging capabilities on other mainstream apps. The update adds ...

Foreigners seeking visas to live in the U.S. might be rejected if they have certain medical conditions, including diabetes or obesity, under a directive issued last week by the Trump administration.

The last time I wrote a LinkedIn-specific news story was way back in February, when I warned of a Lazarus attack that targeted the wrong user. That LinkedIn doesn’t feature more in security news ...

The currencies of developed and emerging nations are increasingly moving in lockstep as political risk weighs on the rich world. The correlation between the two currency blocs has climbed to a ...

More than 92% of patients treated with Daiichi Sankyo and AstraZeneca’s ENHERTU were free of invasive disease at three years DESTINY-Breast05 presented in ESMO Presidential Symposium I alongside ...